MedPath

Role of rifaximin in reducing infectious complications in acute pancreatitis

Not Applicable
Conditions
Health Condition 1: K859- Acute pancreatitis, unspecified
Registration Number
CTRI/2022/07/043978
Lead Sponsor
Anurag Kumar Tiwari
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Not specified
Target Recruitment
0
Inclusion Criteria

Patients aged 18 years to 65 years presenting with their first attack of acute pancreatitis within first 14 days from onset of pancreatitis and have systemic inflammatory response syndrome (SIRS) at presentation will be included in the study.

Exclusion Criteria

Patients with previous history of pancreatic disease, evidence of active infection at presentation, presence of co-morbid malignancy, presence of obesity [BMI >35kg/msq] and not giving consent for study will be excluded.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath